Identification of post acute myocardial infarction patients with potential benefit from prophylactic treatment with amiodarone. A substudy of EMIAT (The European Myocardial Infarct Amiodarone Trial)

M. J. Janse, Marek Malik, A. J. Camm, D. G. Julian, G. A. Frangin, P. J. Schwartz

Research output: Contribution to journalArticle

45 Citations (Scopus)

Abstract

Aims. To perform a retrospective analysis of subgroups of patients enrolled into the European Myocardial Infarct Amiodarone Trial (EMIAT) in order to identify patients who might benefit from prophylactic amiodarone treatment and patients in whom amiodarone might be harmful. Methods. Baseline characteristics of the 1486 patients enrolled in EMIAT were used to investigate the all-cause mortality effect of amiodarone (intention-to-treat) in patients with a left ventricular ejection fraction 30-40% and <30%, in patients with and without arrhythmia signs on Holter recordings, in patients with high and low baseline resting heart rate, in patients on and off beta-blocker treatment, and in a combination of these groups. Results. A univariate analysis suggested that all-cause mortality is reduced on amiodarone in patients with an ejection fraction <30%, with arrhythmia on the initial Holter, on beta-blocker treatment, and with an increased initial heart rate. A trend towards an increase of all-cause mortality was noted in patients with an ejection fraction 30-40%, without arrhythmia on Holter, off beta-blockers, and with a low baseline heart rate. A multivariate analysis suggested that the univariate observations are mutually additive. Conclusions. The study might serve as a basis for future prospective trials where amiodarone could be tested in patients with a recent myocardial infarction, having a reduced left ventricular ejection fraction, a high initial heart rate, and taking beta-blockers.

Original languageEnglish
Pages (from-to)85-95
Number of pages11
JournalEuropean Heart Journal
Volume19
Issue number1
DOIs
Publication statusPublished - Jan 1998

Fingerprint

Amiodarone
Myocardial Infarction
Heart Rate
Therapeutics
Cardiac Arrhythmias
Stroke Volume
Mortality
Multivariate Analysis

Keywords

  • Acute myocardial infarction
  • Amiodarone
  • Arrhythmias
  • Beta-blockers
  • Heart rate
  • Left ventricular function

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Identification of post acute myocardial infarction patients with potential benefit from prophylactic treatment with amiodarone. A substudy of EMIAT (The European Myocardial Infarct Amiodarone Trial). / Janse, M. J.; Malik, Marek; Camm, A. J.; Julian, D. G.; Frangin, G. A.; Schwartz, P. J.

In: European Heart Journal, Vol. 19, No. 1, 01.1998, p. 85-95.

Research output: Contribution to journalArticle

@article{2ef49aa56a674aad8bfd470a332c1f83,
title = "Identification of post acute myocardial infarction patients with potential benefit from prophylactic treatment with amiodarone. A substudy of EMIAT (The European Myocardial Infarct Amiodarone Trial)",
abstract = "Aims. To perform a retrospective analysis of subgroups of patients enrolled into the European Myocardial Infarct Amiodarone Trial (EMIAT) in order to identify patients who might benefit from prophylactic amiodarone treatment and patients in whom amiodarone might be harmful. Methods. Baseline characteristics of the 1486 patients enrolled in EMIAT were used to investigate the all-cause mortality effect of amiodarone (intention-to-treat) in patients with a left ventricular ejection fraction 30-40{\%} and <30{\%}, in patients with and without arrhythmia signs on Holter recordings, in patients with high and low baseline resting heart rate, in patients on and off beta-blocker treatment, and in a combination of these groups. Results. A univariate analysis suggested that all-cause mortality is reduced on amiodarone in patients with an ejection fraction <30{\%}, with arrhythmia on the initial Holter, on beta-blocker treatment, and with an increased initial heart rate. A trend towards an increase of all-cause mortality was noted in patients with an ejection fraction 30-40{\%}, without arrhythmia on Holter, off beta-blockers, and with a low baseline heart rate. A multivariate analysis suggested that the univariate observations are mutually additive. Conclusions. The study might serve as a basis for future prospective trials where amiodarone could be tested in patients with a recent myocardial infarction, having a reduced left ventricular ejection fraction, a high initial heart rate, and taking beta-blockers.",
keywords = "Acute myocardial infarction, Amiodarone, Arrhythmias, Beta-blockers, Heart rate, Left ventricular function",
author = "Janse, {M. J.} and Marek Malik and Camm, {A. J.} and Julian, {D. G.} and Frangin, {G. A.} and Schwartz, {P. J.}",
year = "1998",
month = "1",
doi = "10.1053/euhj.1997.0823",
language = "English",
volume = "19",
pages = "85--95",
journal = "European Heart Journal",
issn = "0195-668X",
publisher = "Oxford University Press",
number = "1",

}

TY - JOUR

T1 - Identification of post acute myocardial infarction patients with potential benefit from prophylactic treatment with amiodarone. A substudy of EMIAT (The European Myocardial Infarct Amiodarone Trial)

AU - Janse, M. J.

AU - Malik, Marek

AU - Camm, A. J.

AU - Julian, D. G.

AU - Frangin, G. A.

AU - Schwartz, P. J.

PY - 1998/1

Y1 - 1998/1

N2 - Aims. To perform a retrospective analysis of subgroups of patients enrolled into the European Myocardial Infarct Amiodarone Trial (EMIAT) in order to identify patients who might benefit from prophylactic amiodarone treatment and patients in whom amiodarone might be harmful. Methods. Baseline characteristics of the 1486 patients enrolled in EMIAT were used to investigate the all-cause mortality effect of amiodarone (intention-to-treat) in patients with a left ventricular ejection fraction 30-40% and <30%, in patients with and without arrhythmia signs on Holter recordings, in patients with high and low baseline resting heart rate, in patients on and off beta-blocker treatment, and in a combination of these groups. Results. A univariate analysis suggested that all-cause mortality is reduced on amiodarone in patients with an ejection fraction <30%, with arrhythmia on the initial Holter, on beta-blocker treatment, and with an increased initial heart rate. A trend towards an increase of all-cause mortality was noted in patients with an ejection fraction 30-40%, without arrhythmia on Holter, off beta-blockers, and with a low baseline heart rate. A multivariate analysis suggested that the univariate observations are mutually additive. Conclusions. The study might serve as a basis for future prospective trials where amiodarone could be tested in patients with a recent myocardial infarction, having a reduced left ventricular ejection fraction, a high initial heart rate, and taking beta-blockers.

AB - Aims. To perform a retrospective analysis of subgroups of patients enrolled into the European Myocardial Infarct Amiodarone Trial (EMIAT) in order to identify patients who might benefit from prophylactic amiodarone treatment and patients in whom amiodarone might be harmful. Methods. Baseline characteristics of the 1486 patients enrolled in EMIAT were used to investigate the all-cause mortality effect of amiodarone (intention-to-treat) in patients with a left ventricular ejection fraction 30-40% and <30%, in patients with and without arrhythmia signs on Holter recordings, in patients with high and low baseline resting heart rate, in patients on and off beta-blocker treatment, and in a combination of these groups. Results. A univariate analysis suggested that all-cause mortality is reduced on amiodarone in patients with an ejection fraction <30%, with arrhythmia on the initial Holter, on beta-blocker treatment, and with an increased initial heart rate. A trend towards an increase of all-cause mortality was noted in patients with an ejection fraction 30-40%, without arrhythmia on Holter, off beta-blockers, and with a low baseline heart rate. A multivariate analysis suggested that the univariate observations are mutually additive. Conclusions. The study might serve as a basis for future prospective trials where amiodarone could be tested in patients with a recent myocardial infarction, having a reduced left ventricular ejection fraction, a high initial heart rate, and taking beta-blockers.

KW - Acute myocardial infarction

KW - Amiodarone

KW - Arrhythmias

KW - Beta-blockers

KW - Heart rate

KW - Left ventricular function

UR - http://www.scopus.com/inward/record.url?scp=0031888965&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031888965&partnerID=8YFLogxK

U2 - 10.1053/euhj.1997.0823

DO - 10.1053/euhj.1997.0823

M3 - Article

C2 - 9503180

AN - SCOPUS:0031888965

VL - 19

SP - 85

EP - 95

JO - European Heart Journal

JF - European Heart Journal

SN - 0195-668X

IS - 1

ER -